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A monoclonal antibody against GBM heparan sulfate induces an acute
selective proteinuria in rats. After immunization of mice with partially-
purified heparan sulfate proteoglycan (HSPG) isolated from rat glomer-
uli, a monoclonal antibody (mAb JM-403) was obtained, which was
directed against heparan sulfate (HS), the glycosaminoglycan side chain
of HSPG. In ELISA it reacted with isolated human glomerular base-
ment membrane (GBM) HSPG, HS and hyaluronic acid, but not with
the core protein of human GBM HSPG, and not with chondroitin sulfate
A and C, dermatan sulfate, keratan sulfate and heparin. Furthermore, it
did not bind to laminin, collagen type IV or fibronectin. Specificity of
JM-403 for HS was also suggested by results of inhibition studies, which
found that intact HSPG and HS, but not the core protein, inhibited the
binding of JM-403 to HS. In indirect immunofluorescence on cryostat
sections of rat kidney, a fine granular to linear staining of the GBM was
observed, along with a variable staining of the other renal basement
membranes. Pretreatment of the sections with heparitinase completely
prevented the binding of mAb JM-403, whereas pretreatment with
chondroitinase ABC or hyaluronidase had no effect. The precise
binding site of mAb JM-403 was investigated by indirect immunoelec-
tron microscopy. It revealed a diffuse staining of the whole width of the
GBM. One hour after intravenous injection of JM-403 into rats, the
mAb was detected along the glomerular capillary wall in a fine granular
pattern, which shifted towards a more mesangial localization after 24
hours. No binding was observed anymore by day 15. Intravenous
injection induced a dose-dependent, transient and selective proteinuria
that was maximal immediately after the injection. Administration of 2
mg of JM-403 increased the urinary albumin excretion within the first 24
hours after injection from (mean SD) 177 19 to 20,755 10,310
jsgI24 hr (P < 0.01); the urinary IgG excretion increased from 5.8 2.9
to 236.1 132.2 ig/24 hr (P < 0.03); the selectivity index (clearance
IgG/clearance albumin) decreased from 0.33 0.12 to 0.12 0.05 (P <
0.004).
Heparan sulfate (HS) is thought to play an important role in
the permselective properties of the glomerular basement mem-
brane (GBM) [1—3]. In several clinical and experimental glomer-
ulopathies an increased permeability of the GBM is associated
with a diminished HS content of the GBM [4—9]. Moreover,
enzymatic removal of HS from the glomerular capillary wall
increases the passage of native ferritin and albumin into the
urinary space [10, 11]. These data were corroborated by inves-
tigations which showed that after intrarenal or intravenous
Received for publication May 22, 1991
and in revised form August 28, 1991
Accepted for publication August 30, 1991
© 1992 by the International Society of Neplirology
injection of cationic molecules, GBM permeability increased
due to the neutralization of HS-associated anionic sites of the
glomerular capillary wall [12—16]. However, the significance of
HS for the permselectivity of the GBM and for the induction of
proteinuria is still not completely understood, and a number of
controversies still exist [17—201.
To study the impact of HS for the permselective properties of
the GBM in more detail, antibodies against HS can be an
important tool. There are some reports with regard to the
nephritogenic potential of polyclonal antibodies against the core
protein of GBM heparan sulfate proteoglycan (HSPG) [2 1—24].
However, at present there are no studies which describe the
nephritogenic effects of antibodies against HS, the glycos-
aminoglycan (GAG) side chain of HSPG. This is probably due
to the difficulty to raise anti-HS antibodies because of the low
immunogenicity of these polysaccharide structures. Kure and
Yoshie [25] described a syngeneic monoclonal antibody (mAb)
to murine meth-A sarcoma which recognizes HS. The prepara-
tion of an mAb against HS of Engelbreth-Holm-Swarm (EHS)
tumor proteoglycan was also reported [26]. It was recently
applied in studies on cerebral amyloid deposits [27, 28].
In this paper, we describe the production and characteriza-
tion of an mAb against GBM HS. After intravenous (i.v.)
injection in rats an immediate, transient binding of mAb to the
GBM occurred with a concommitant development of a selective
proteinuna.
Methods
Partial purjfication of rat glomerular HSPG
All procedures were carried out at 4°C, in the presence of a
mixture of proteinase inhibitors (1 mrvi phenylmethanesulpho-
nyl fluoride, 5 m benzamidine hydrochloride, 10 m N-ethyl-
maleimide, 0.1 M 6-aminohexanoic acid, 5 mrt iodocetamide
and 10 mt EDTA). Rat glomeruli (9.3 g) were isolated from rat
kidney cortices (715 g) by the differential sieving technique
according to Meezan et al [29]. The glomerular suspension was
maintained for more than 85% of glomeruli and was only
contaminated with a few tubular fragments, but not with
interstitial tissue. Glomeruli were homogenized using a Sorvall
omnimixer, and extracted twice overnight in 150 ml 4 M
guanidine HC1I5O m sodium acetate buffer, pH 5.8. The
combined supernatants obtained after centnfugation at 40,000 g
for 30 minutes, were concentrated to 35 ml by ultraffitration on
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an Amicon XM-50 filter, and extensively dialyzed against 7 a
ureallo mM Tris-HCI buffer, pH 6.8. After centrifugation
(40,000 g for 30 mm) the supernatant was purified on a DE-52
cellulose column (2.5 x 20 cm) equilibrated with 7 M urea/b
ifiM Tris-HC1 buffer, pH 6.8, The bound material was eluted by
a linear 0 to 2 M sodium chloride gradient. The protein content
of the fractions was determined spectrophotometrically at A280
and the glycosaminoglycan (GAG) content by the Farndale
assay [30]. During elution, two protein peaks appeared, the first
containing one Farndale-positive peak, the second comprising
two Farndale-positive peaks (Fig. 1). This elution profile was
completely identical to that obtained during purification of
human glomerular extracts. From this previous analysis, for
which we used human specific anti-HSPG antibodies [311, we
knew that HSPG was only present in the middle Farndale-
positive peak. For that reason fractions 69 to 75 were pooled
and dialyzed extensively against PBS. Comparison of the
proteinlGAG ratio of the 7 M urea extract before DE-52
chromatography of 51.5 with that of 4.3 of the pooled fractions
69 to 75 after DE-52 chromatography shows an evident enrich-
ment for HSPG, as indicated by this decreased protein/GAG
ratio. This ratio is of the same order as for isolated human GBM
HSPG 1311. This crude glomerular HSPG preparation was used
for immunizations.
Hybridoma production
Female BALB/c mice were immunized intraperitoneally at
days 0 and 30 with 50 jtg of the gbomerular HSPG preparation
dissolved in 150 d PBS and emulsified with an equal volume of
complete Freund's adjuvant. At days 60, 61 and 62 the mice
received an intravenous booster injection of 15 jig of the same
immunogen in 0.15 ml PBS. At day 63 the mice were sacrificed,
their spleens were removed, and splenocytes were fused with
the non-producing 5P2/0 mouse myeloma cell line, according to
the principles of Kohler and Milistein [32]. Syngeneic peritoneal
macrophages (10,000 to 20,000 cells/well) were used as feeder
cells. Wells with growing hybridomas were screened in ELISAs
with either the immunogen or HS as coated antigen, and by
indirect immunofluorescence (IF) on rat kidney cryostat sec-
tions. After HAT selection, screening and expansion, cell
cultures were transferred to HEPES-buffered RPMI-1640 cul-
ture medium containing 10% fetal calf serum, gentamycin (40
jig/mI), pyruvate (110 us/mI) and glutamine (292 pg/ml). Se-
lected wells were recloned by limiting dilution until all sub-
clones displayed the same reactivity pattern. All cells were
cultured in an humidified incubator at 37°C with 95% air and 5%
CO2. The antibody subclass was determined in ELISA using
subclass-specific antibodies conjugated to peroxidase (Southern
Biotechnology Associates Inc., Birmingham, Alabama, USA).
Ten to twelve weeks old, pristane (2,6,10,14 tetramethylpenta-
decane, Janssen Chimica, Beerse, Belgium) primed, male
BALB/c mice received 3 x 106 viable hybridoma cells intraper-
itoneally. After one to three week ascites was drained, left to
clott overnight at 4°C, centrifuged, filtered through 0.2 jim
filters, aliquoted and stored at —20°C until use. The 1gM
concentration of the ascites was determined by the single
diffusion technique according to Mancini, Carbonara and Her-
emans [331, using purified mouse 1gM (Bionetics, Kensington,
Maryland, USA) as the standard and goat anti-mouse 1gM
(Sigma Chemical Co., St. Louis, Missouri, USA) as antibody.
Characterization of mAb
ELISA studies. Anti-glycosaminoglycan (GAG) reactivity
was measured in ELISA as described [34] using protamine
chloride precoating to ensure sufficient binding of the negatively
charged GAGs to the plates. The following GAGs were used:
HS isolated from bovine kidney (Seikagaku, Tokyo, Japan);
chondroitin sulfate A and C isolated from whale cartilage
(Sigma); dermatan sulfate isolated from porcine skin (Sigma);
keratan sulfate isolated from calf cartilage (from Dr. R. van de
Stadt, Jan van Breemen Institute, Amsterdam, The Nether-
lands), heparin (Thromboliquine, Organon Teknika, Oss, The
Netherlands), and hyaluronic acid (HA) isolated from human
umbilical cord (Sigma). The ELISA for determination of anti-
body reactivity against glomerular HSPG (pool 69-75), human
GBM HSPG (isolated as described previously [31]), and its core
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Fig. 1. Chromatography of the extract of rat
glomeruli on DE-52 cellulose. Elution took
place with 7 M urea/b mat Tris buffer, pH
7.6, followed by a gradient starting at fraction
40 of 0 to 2 M NaC1 in the same buffer.
Fractions were analyzed for protein (A280)
(— —El-.—) and sulfated GAGs (A525, Farndale
assay) (a—). Fractions 69-75 (indicated by the
bar) were pooled and dialyzed against PBS.
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protein [obtained after treatment of GBM HSPG with trifluo-
romethane suiphonic acid (TFMS) [31]], laminin (from the
mouse EHS tumor; Sigma), collagen type IV (from the mouse
EHS tumor, Collaborative Res. Inc., Bedford, Massachusetts,
USA) and fibronectin (from rat plasma, Calbiochem, La Jolla,
California, USA) was carried out according to Rennard et al
[35]. As positive controls in the ELISAs were used: serum of
the mouse selected for fusion (positive control for pool 69-75),
rabbit anti-EHS laminin (GIBCO Europe, Breda, The Nether-
lands), rabbit anti-mouse collagen type IV (Collaborative Res.
Inc.) and goat anti-rat fibronectin (Calbiochem). The inhibition
ELISA was carried out with the different GAGs and with
isolated human GBM HSPG or its core protein as inhibitor. For
this inhibition ELISA, mAb JM-403 was diluted to a concen-
tration giving 80% of the maximal ELISA signal and preincu-
bated with an equal volume of 60 d inhibitor at concentrations
ranging from 0.2 to 100 g/ml for one hour at 37°C and
subsequently for one hour at 4°C and tested in the ELISA with
HS as coated antigen. Results are expressed as % inhibition of
the ELISA signal calculated as: [1 — (A450 + inhibitor/A450 —
inhibitor)] x 100%.
Immunofluorescence (IF). Indirect IF was performed on 2
m cryostat sections of rat kidneys, which were incubated with
25 d of primary antibody (culture supernatant of hybridoma
cells) for 30 minutes at 20°C. Incubation of the sections with a
non-relevant mAb served as a negative control. After washing
with PBS, binding was visualized by incubating the sections for
30 minutes at 20°C with 25 i1, 1:500 diluted FITC-Iabeled
F(ab)2 fragments of sheep anti-mouse IgG, heavy and light
chains specific (Cappel, Organon Teknika, Turnhout, Belgium)
or with FITC-labeled goat anti-mouse 1gM, Fc specific (Nordic,
Tilburg, The Netherlands), 1:50 diluted in PBS containing 1%
bovine serum albumin (BSA), 0.05% sodium azide and 5%
normal rat serum. Direct IF was performed on 2 m cryostat
sections of rat kidneys snap frozen in liquid nitrogen. Sections
were incubated for 30 minutes with FITC-labeled goat anti-
mouse 1gM, Fc specific, 1:50 diluted in PBS containing 1%
BSA, 0.05% sodium azide and 5% normal rat serum. Sections
were washed with PBS, embedded in Aqua Mount (pH 7.0) and
examined with a Leitz fluorescence microscope equipped with
a Ploemopak epi-illuminator. Pretreatment of the sections was
performed by incubating unfixed cryostat sections for 30 min-
utes at 37°C in the appropriate buffer with 1 U/mI heparitinase
(Seikagaku, Tokyo, Japan), 0.5 U/ml chondroitinase ABS (Sig-
ma) or 50 U/mI hyaluronidase (Sigma). After washing with PBS,
indirect IF with mAb JM-403 was performed. As a positive
control, goat antibodies against human GBM HSPG-core pro-
tein were used, which cross react with rat GBM HSPG. Indirect
IF was performed as described above, using FITC-labeled
rabbit anti-goat IgG (Kallestad, Chaska, Minnesota, USA) to
detect the bound goat antibodies. Inhibition studies in indirect
IF on kidney sections were carried out by incubating mAb
JM-403 in the presence of GBM HSPG, its core protein,
different GAGs or the monosaccharide components of HS and
HA, N-acetyl-glucosamine and glucuronic acid in a concentra-
tion of 100 pgIml.
Immunoelectron microscopy (IEM). For indirect IEM, rat
kidneys were perfused for 10 minutes via the retrograde aortic
route with PBS, followed by perfusion with a mixture of
periodate-!ysine-2% paraformaldehyde (PLP) fixative for 10
minutes. Small pieces of renal cortex were further immersed in
the same fixative for an additional three hours, cryoprotected in
2.3 M sucrose for 45 minutes, and snap frozen in liquid nitrogen.
Twenty-five pm cryostat sections were incubated with mAb
JM-403, diluted 1:30 in PBS containing 1% BSA, for 18 hours at
4°C and washed several times with PBS afterwards. For the
direct IEM, rats were injected i.v. with one ml JM-403 ascites.
After one hour, the kidneys were perfused and fixed, cryopro-
tected and stored as described for the indirect IEM. Twenty-
five m cryostat sections were cut. Sections for the direct as
well as for the indirect IEM were incubated with a peroxidase-
labeled rabbit anti-mouse Ig (Dakopatts, Copenhagen, Den-
mark), diluted 1:20 in PBS-1% BSA for 90 minutes. After
several washes in PBS, the sections were preincubated in 0.05%
diaminobenzidine (DAB) medium containing 0.6% TRIS for 10
minutes, followed by the same medium with addition of 10 jd of
30% H,02 for 10 minutes. After washing in H20 for 18 hours,
the sections were post-fixed in 0.1 M phosphate buffered 1%
0s04 pH 7.4 for 30 minutes at room temperature, dehydrated,
and embedded in Epon 812. Thin sections were prepared on a
LKB Ultratome, and examined in a Philips 300 electron micro-
scope.
Nephritogenicity of inAb JM-403
Animals. The nephritogenic properties of mAb JM-403 were
investigated in male Wistar rats of 200 g, bred at our animal
laboratory. During the experiments rats were placed in individ-
ual metabolic cages, with free access to water and standard
chow.
Experimental design. In the first experiment, rats were in-
jected i.v. in the tail vein under ether anaesthesia with one ml of
JM-403 ascites (containing 1 mg 1gM/mi). Rats were sacrificed
one hour, 24 hours and 14 days after injection. Kidneys were
removed, snap frozen in liquid nitrogen and used for direct IF
as described above. In the second experiment, five groups of
five rats were used. Rats were injected i.v. with respectively
0.032, 0.125, 0.5 and 2 mg 1gM (JM-403 ascites, in PBS with a
final volume of 2 ml). In control experiments rats received 2 ml
ascites in PBS containing 2 mg of a non-relevant 1gM mAb
(anti-human B-cell idiotype). After injection rats were placed in
individual metabolic cages and 24-hour urine specimens were
sampled during 10 days. Thereafter, a blood sample was taken
from each rat. In the third experiment 10 rats received 0.5 ml
JM-403 ascites (containing 0.5 mg 1gM) i.v. Immediately after
injection rats were placed in metabolic cages and urine was
sampled every two hours, during 24 hours.
Urine analysis. Urinary albumin concentrations were deter-
mined by rocket immunoelectrophoresis according to Laurel!
[36], using goat anti-rat albumin and rat albumin as the standard
(both from Nordic, Tilburg, The Netherlands). Urinary IgG
concentrations were determined in a capture ELISA, using rat
IgG (Nordic), 2 to 2000 ng/ml as the standard. Polystyrene
microtiter plates (Greiner) were coated overnight at room
temperature with affinity-purified goat anti-rat IgG, heavy and
light chains specific (Cappel), 1:500 in 0.05 M carbonate buffer,
pH 9.6, 100 p1/well. After washing with PBS containing 0.05%
Tween-20 (PBS-T), urines were diluted 1:4 to 1:4096 in PBS-T
containing 0.2% BSA, 100 p1Iwell. Plates were incubated for
one hour at 37°C. After washing with PBS-T, 100 p1 peroxidase
conjugated, affinity-purified goat anti-rat IgG, (Cappel), 1:500
Fig. 2. Antigen spec(ficity of mAb JM-403. A.
Reactivity of mAb JM-403 in ELISA. MAb
JM-403 bound to HS (_*_) and HA (—LI—), but
not to the other GAGs (chondroitin sulfate A
and C, dermatan sulfate, keratan sulfate and
heparin) (—C>—). Binding also occurred to
isolated human GUM HSPG (—V—), whereas
its core protein was not recognized (—A—). B.
Dose-dependent inhibition of mAb JM-403 in
ELISA. HS was used as coated antigen.
Inhibition was found with intact human GBM
HSPG (—V—), with HS (_*_) and with HA
(—D—), but not with the other GAGs (—C>—) or
the HSPG core protein (—A--).
in PBS-T, 0.2% BSA were added to the wells and incubated for
another hour at 37°C. Finally, after washing with PBS-T, 100 d
freshly prepared substrate solution (0.8 mg/mi 5-aminosalicylic
acid in 50 rn phosphate buffer, pH 6.0, containing 0.8 itl/ml
30% vol/vol H202) were added to each well. After 30 minutes
the absorbance was measured at 450 nm in a Titertek multiscan.
Serum albumin and IgG concentrations were determined as
described above for urine. The selectivity index was defined as
clearance IgG/clearance albumin.
Statistical analysis
For statistical analysis of results with a normal distribution
the paired it-test was used, for not normally distributed data the
Wilcoxon's test. Probability values <0.05 were regarded as
significant. All values are expressed as mean SD.
Results
Production of monoclonal antibodies
After immunization of female BALB/c mice with the glomer-
ular HSPG preparation and fusion of the splenocytes with the
non-producing SP2/0 myeloma cell line, growing hybridomas
were screened in indirect IF on rat cryostat kidney sections and
in ELISA oa the immunogen and HS. After this screening
procedure one out of 700 clones was positive. This hybridoma,
called JM-403, was subcloned twice until all subclones dis-
played the same reactivity pattern. MAb JM-403 belongs to the
1gM class, Ascites contained I mg IgM/ml.
Characteristics of mAb JM403
ELISA studies. The reactivity pattern of mAb JM-403 in
ELISA with different GAGs is shown in Figure 2A. A clear
reactivity was observed with HS and hyaluronic acid (HA), but
no binding occurred to chondroitin sulfate A and C, dermatan
sulfate, keratan sulfate or heparin. Since mAb JM-403 cross
reacted with human tissues (not shown), we tested its binding to
isolated human GUM HSPG and its core protein in ELISA. The
core protein was obtained after treatment with TFMS, a method
known to cleave all saccharide units [311. Figure 2A also shows
that mAb JM-403 bound to human GBM HSPG in ELISA, but
not to its core protein. The GAG specificity of mAb JM-403 was
confirmed by the inhibition ELISA shown in Figure 2B. Both
HS and HA were able to inhibit the binding of mAb JM-403 to
HS in a dose dependent manner. None of the other GAGs, even
at the highest concentration (100 p.g/ml), showed any inhibition.
Cellulose acetate electrophoresis of HA used in our experi-
ments did not show any contamination of HA with HS, which
excluded impurity of the HA preparation as a cause of this
binding. Figure 2B also showed that the intact HSPG molecules
were able to inhibit the binding of mAb JM-403 to HS in ELISA
in a dose-dependent manner, whereas the core protein did not
inhibit at all. This lack of inhibition of the core protein was due
to the removal of HS-side chains and not to denaturation or
degradation of the core protein by the TFMS treatment, since
the core protein inhibited equally effectively as intact HSPG for
the binding of an anti-HSPG core mAb to HSPG (data not
shown). All results corroborated the HS specificity of mAb
JM-403. In ELISA mAb JM-403 did not bind to other basement
membrane components, that is, laminin, collagen type IV or
fibronectin (data not shown).
Histological studies. By indirect IF on 2 gm cryostat sections
of a rat kidney, mAb JM-403 bound strongly to the GBM and
Bowman's capsule in a fine granular to linear pattern (Fig. 3A).
Also the basement membranes of endothelial cells and of
smooth muscle cells in arteries and arterioles were positive, as
well as some tubular basement membranes (TBMs), although
this staining was much weaker and had a variable intensity (Fig.
3B). The staining pattern of the glomerulus corresponded very
well to that of antibodies directed against the core protein of
GBM HSPG (Fig. 3D). The HS specificity of mAb JM-403 was
further substantiated by the finding that binding was completely
prevented by pretreatment of the sections with heparitinase, an
enzyme which degrades HS (Fig. 3C). This pretreatment did not
degrade the core protein of HSPG, since antibodies against the
HSPG core protein still bound (Fig. 3D). No alterations in
staining pattern were observed after pretreatment of the sec-
tions with chondroitinase ABC or hyaluronidase. Binding of
mAb JM-403 to the sections could also be inhibited by the
addition of 100 jsg/ml human GBM HSPG, HS or HA to the
mAb before incubation of the sections, but not by the addition
of the other GAGs or the core protein of human GBM HSPG,
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Fig. 3. Indirect IF of a rat kidney using mAb
JM-403 (A, B and C) and a polyclonal
antibody against the GBM HSPG-core protein
(D). Sections shown in photomicrographs C
and D were pretreated with heparitinase. Note
the absence of staining with niAb JM-403 after
heparitinase pretreatment (C), whereas
binding of the anti-HSPG-core antibodies was
unaltered (D) (A x 508; B x 254; C x 422; D
x 264).
Fig. 4. JEM photomicrographs illustrating the
in vitro and in vivo binding of mAb JM-403.
A. Indirect IEM showed a clear staining of
the whole GBM. B. Direct IEM of a capillary
wall prepared one hour after i.v. injection of 1
ml JM-403 ascites (1 mg 1gM/mi). Reaction
product was located in the lamina rara interna
of the GBM and its border adjacent to the
endothelium. In some but not all glomeruli, a
faint staining was observed of the endothelial
cell membranes (A x 13,000; B x 18,850).
nor by the addition of the monosaccharide components of HS
and HA, N-acetyl-glucosamine and glucuronic acid. Tissues
known to contain large amounts of HA (skin and umbilical vein)
only revealed a basement membrane staining in indirect IF.
Moreover, this staining was completely abolished after pre-
treatment of the sections with heparitinase, whereas hyaluroni-
dase did not alter the staining pattern, indicating that mAb
JM-403 did not recognize HA in situ. In indirect JEM, mAb
JM-403 bound diffusely to the whole width of the GBM (Fig.
4A). Occasionally staining was observed of the cell membranes
of endothelial cells and the foot processes of epithelial cells. It
is difficult to distinguish whether this is due to binding to the cell
membrane or to a diffusion artifact.
Nephritogenicity of anti-HS mAb JM-403
After intravenous injection mAb JM-403 immediately local-
ized predominantly along the GBM, as indicated by direct IF
one hour after injection (Fig. 5A). A fine granular staining of the
GBM was observed along with some staining of the mesangium.
Twenty-four hours after injection, the staining pattern had
shifted towards a more mesangial localization, while the stain-
ing in the GBM had decreased considerably (Fig. 5B). Two
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Fig. 5. Direct IF of rat kidneys obtained one hour (A), twenty-four hours (B) or two weeks (C) after Lv. injection of 500 sg mAb JM-403, There
was a shift fromGBM binding at one hour (A) to a more mesangial localization at twenty-four hours (B). After two weeks no mAb was detectable
in the glomeruli (C) (A, B and C X 380).
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weeks after ittiection, hardly any antibody could be detected in
the glomerulus, however, a weak staining of Bowman's capsule
remained (Fig. SC). These immunohistological data indicate a
direct, transient binding of anti-HS mAb JM-403 along the
GBM.
Direct JEM visualized the bound mAb JM-403 mainly at the
inner side of the GBM one hour alter i.v. injection (Fig. 4B).
Sometimes, reaction products were also observed on endothe-
hal cells, but not in every glomerulus. No binding occurred to
epithelial cells. Additional staining was observed in the parame-
sangial areas. This staining pattern corresponded well to the IF
staining depicted in Figure 5A.
To test whether this GBM binding of JM-403 could alter the
permeability of the GBM, groups of five rats were injected i.v.
with different doses of mAb, respectively 0.032, 0.125, 0.5 and
2 mg. A dose-dependent albuminuria was induced alter 0.5 and
2 mg mAb, which was maximal at day 1 and declined thereafter
(Fig 6A). To investigate whether the induced proteinuria was
selective, urinary excretion of IgG was also measured. The
urinary IgG excretion followed the same pattern as the albumin
excretion, although at a lower level (Fig. 6A). If we calculated
the selectivity index (clearance IgG/clearance albumin) we
found that the proteinuria was selective (Fig. 6B). The values
for the mean (± SD) of the urinary albumin and IgG excretion in
the first 24 hours after the i.v. injection of either 0.5 or 2 mg
mAb JM-403 and the corresponding selectivity indexes, to-
gether with the baseline values for the different parameters are
given in Table 1. Control studies in five rats, receiving ascites
containing 2 mg of a non-relevant 1gM mAb (anti-human B-cell
idiotype) i.v., did neither show any glomerular localization of
mouse 1gM, nor development of albuminuria. Since the albu-
minuria was maximal at day 1, we analyzed in 10 rats the
kinetics of the albumin excretion in two-hour urine samples
during th first 24-hours after injection of 0.5 mg mAb JM-403.
Figure 7 shows that the albumin excretion is maximal in the first
two hours after injection with a gradual decline thereafter. The
magnitude of the albuminuria paralleled the glomerular binding
of the mAb as seen by direct IF (Fig. 5).
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Fig. 6. Urinary protein excretion per 24 hours after i.v. injection of 0.032 (—0--), 0.125 (—s—), 0.5 (—0—) and 2 (——) mg mAb JM-403. Each group
consisted Out of 5 rats. Day 0 gives baseline levels before injection of mAb. Graph A shows the course of the albuminuria (solid lines) and the
urinary IgG excretion (dashed lines), both expressed as ig/24 hours. Graph B shows the course of the selectivity index of the proteinuria (clearance
IgG/clearance albumin). Urinary IgG excretion and selectivity indexes are given for the rats that received 0.5 and 2 mg mAb.
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Table 1. Mean (± SD) urinary albumin and IgG excretion after i.v. injection of a 2 ml dilution of JM-403 ascites containing either
1gM in the first 24 hours after injection (day 1) compared with the normal excretion (baseline)
0.5 or 2 mg
0.5 mg i.v. 2 mg i.v.
baseline day 1 P value baseline day 1 P value
Albumin excretion
rigI24 hr
IgG excretion
pg/24 hr
Selectivity index
284 120 6,486 4,640 <0.04 177 19 20,755 10,310
5.7 1.5 58,6 42.7 <0.05 5,8 2.9 236.1 132.2
0.37 0.20 0.15 0.07 < 0.03 0.33 0.12 0.12 0.05
<0.01
<0.03
<0.004
The selectivity index of the proteinuria (clearance IgO/clearance albumin) is also given.
Discussion
In this report we describe the production of a nephritogenic
mAb against GBM HS. The HS-specificity of mAb JM-403 can
be concluded from the following experimental data: (a) in
ELISA a strong reactivity was observed with HS, but not with
chondroitin sulfate A or C, dermatan sulfate, keratin sulfate or
heparin; (b) mAb JM-403 bound in ELISA to isolated human
GBM HSPG, but not to its core protein without HS-chains; (c)
pretreatment of kidney sections with hepantinase prevented the
binding of JM-403, whereas the binding of polyclonal antibodies
against the core protein of GBM HSPG was unaffected. Pre-
treatment with chondroitinase ABC and hyaluronidase did not
influence the binding of JM-403; (d) the binding of mAb JM-403
to HS in ELISA as well as the binding to the kidney sections in
indirect IF could be inhibited by human GBM HSPG and HS,
but not by other GAGs or the HSPG core protein.
Besides binding to HS, mAb JM-403 also reacted with HA.
Interestingly, Fillit et a! described two mAbs against HA, from
which one bound to HS [37]. They also demonstrated in sera of
patients with post-streptococcal glomerulonephritis the pres-
ence of antibodies against HS, which cross reacted with HA
[38]. Their and our findings indicate that HS and HA contain
cross reactive epitopes. Both HA and HS contain the same
basic structure of repeating disaccharide units of N-acetyl-
glucosamine and glucuronic acid. Apparently the presence of
0- and N-linked sulfate is not important for JM-403 binding
since HA. does not contain these components. On the other
hand, mAb JM-403 exhibits no affinity for heparin that has more
iduronic acid and sulfate groups than HS. The binding of mAb
JM-403 to HS could not be inhibited by glucuronic acid or
N-acetyl-glucosamine. These findings suggest that the epitope
may be located within a cluster of unsulfated glucuronic acid—
N-acetyl-glucosamine disaccharide units. The fact that HA
present in cryostat sections of skin and umbilical vein (tissues
known to contain large amounts of HA) did not stain with mAb
JM-403 in indirect IF and the absence of an effect of pretreat-
ment of these sections with hyaluronidase suggests that the
epitope on HA, which is recognized by mAb JM-403, is hidden
in vivo. This could be due to the fact that in situ, HA is bound
to proteoglycans and proteins, thereby forming large molecular
complexes, which may result in the masking of the JM-403
recognized epitope, which is set free after isolation of HA.
Comparison of the characteristics of mAb JM-403 with those
of previously described mAbs against HS [25, 27] indicates
differences in epitope specificity. Kure and Yoshie [25] de-
scribed an anti-HS mAb directed against an epitope which is
related to 0-sulfated and N-acetylated glucosamine present in
cell surface-associated HS. Snow et al [27] recently described
an mAb against a glucosamine sulfate a! —'p4 glucuronic acid in
HS of mouse EHS HSPG. Both mAbs did not bind to other
GAGs, including HA and heparin.
In indirect IF on cryostat sections of rat kidneys, the GBM,
Bowman's capsule and the basement membranes of endothelial
cells and of smooth muscle cells in arteries and arterioles
stained much more intensely than the TBMs. The latter staining
was variable and much weaker; some TBMs were even nega-
tive, which seemed to be related to the different segments of the
nephron. In indirect IEM, we observed that the whole width of
the GBM was stained by mAb JM-403. At first glance this seems
to be in contrast with the findings of Stow, Sawada and
Farquhar [39], who found that the HSPG molecule was concen-
trated in both laminae rarae of the GBM. However, their results
were obtained after a short (2 to 4 hr) incubation of the sections
with the anti-HSPG antibodies. In accordance with our results,
they also found a diffuse staining of the whole GBM after an
overnight incubation. Alternatively, differences in staining pat-
terns can also be explained by differences in epitope specificity,
since their antiserum was directed against the core protein of
GBM HSPG, whereas our mAb recognizes the HS chain.
The i.v. administration of mAb-403 induced an acute selec-
tive proteinuria. This shortlasting albuminuria was paralleled by
a transient binding of anti-HS mAb JM-403 along the GBM.
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Fig. 7. Albumin excretion of two-hour urine specimens, sampled dur-
ing the first 24 hours after i.v. injection of 500 g mAb JM-403. Note
that the increase of albumin excretion occurred immediately after
injection of mAb. Statistical significance between urinary albumin
excretion before and in the two-hour urine specimens after injection of
mAb is indicated by *** < 0.001; < 0.01; < 0.05.
122 van den Born et a!: Nephritogenic anti-heparan sulfate antibody
Similar transient binding kinetics were found after i.v. admin-
istration of exogenous or endogenous cationic molecules [6, 12,
13, 40,41]. Their binding to the anionic sites of the GBM is also
accompanied by a short bout of albuminuria. Furthermore,
injection of polycations led to a preferential leakage of albumin
compared to IgG [12, 131, like we found with our mAb. These
similarities suggest that, like polycations, mAb JM-403 neutral-
izes the HS-associated anionic sites of the GBM and decreases
the charge-selective properties of the GBM, favoring the uri-
nary excretion of negatively-charged serum proteins like albu-
min. Whether binding of mAb JM-403 to GBM HS can induce a
local inflammatory response in addition remains to be investi-
gated.
These in vivo experiments were done with unpurified ascites
containing mAb JM-403, since the procedures we used to purify
the 1gM mAb [42, 431 had a poor recovery and a substantial loss
of anti-HS specificity. We performed control studies with
ascites containing 2 mg of a nonrelevant 1gM mAb. In these rats
neither glomerular binding nor albuminuria was detected.
It is tempting to speculate that the quick disappearance of the
mAb from the GBM and the short period of albuminuria is
related to the 1gM isotype of the mAb. The large molecular
mass of the 1gM molecules (900 kDa) probably prevents pene-
tration into the GBM, and thereby restricts binding to HS
present in the lamina rara interna of the GBM. This is exactly
the localization of mAb JM-403 which we found with direct
IEM after i.v. injection (Fig. 4B). In other models of glomerular
injury caused by subendothelial immune deposits, like the Con
A-ferritin/anti-ferritin model [44], the immune complexes dis-
appear within 24 hours, in contrast to subepithelial immune
deposits which persist for a long time. The final proof has to
come from the kinetics of intraglomerular binding and the
course of albuminuria after administration of anti-HS mAbs of
the IgG isotype, since one can expect that this isotype pene-
trates the GBM more easily and can induce subepithelial
immune deposits in addition to subendothelial localization, as
was observed for antibodies against the core protein of HSPG
[22, 23]. The two other mAbs against HS that have been
described [25, 27] were not tested for their nephritogenic
potential. Two other studies have claimed a role for anti-HS
antibodies in nephritis. Fillit et a! [38] detected anti-HS anti-
bodies in sera of patients with acute post-streptococcal nephri-
tis. Whether these antibodies have a pathogenic significance for
the glomerulonephritis is difficult to prove. In another study [45]
Abrass and Cohen immunized rats with commercially available
HS and investigated the role of anti-HS antibodies in the
development of glomerular injury. Binding of anti-HS antibod-
ies in the glomerulus induced a mild inflammatory reaction and
a reduction of glomerular filtration rate, but no abnormal
proteinuria. Unfortunately however, their HS preparation was
contaminated with a 60 kDa protein, and the HS-specificity of
the antibodies was not proven unequivocally. Antibodies
against the core protein of HSPG are nephritogenic after
intravenous injection. A mild form of anti-GBM-like nephritis
occurred with [23] or without [22] the development of albumi-
nuria.
In summary, our results show that antibodies to HS are
nephntogenic and can induce a selective proteinuria, probably
secondary to the neutralization of HS-associated anionic sites
in the GBM.
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